{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:54:23Z","timestamp":1773046463654,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002946","name":"Deutsches Zentrum f\u00fcr Luft- und Raumfahrt","doi-asserted-by":"publisher","award":["01EO2106"],"award-info":[{"award-number":["01EO2106"]}],"id":[{"id":"10.13039\/501100002946","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Fabry disease (FD) is a multisystemic disease affecting the heart and the kidneys of affected patients. In addition to FD-specific treatment, patients require concomitant medication for cardio- and nephroprotection. Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) are recommended for patients with heart failure and\/or kidney disease, but efficacy data for FD are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      In this multicenter study (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), the effects of SGLT2i therapy after 12\u00a0months of treatment in 48 patients (12 females) on FD-specific therapy were examined. Patients were retrospectively analyzed at three time points (before SGLT2i:\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>-1<\/jats:sub>\n                      ; SGLT2i start:\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      ; and end of observation:\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>+1<\/jats:sub>\n                      ). Patients showed advanced cardiac manifestations with a high frequency of left ventricular hypertrophy (LVH) (females: 81.8% and males: 90.0%) at\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      . Males presented with a significantly lower left ventricular ejection fraction LVEF (56 [29\u201373]% versus 65 [38\u201378]%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0113). There were no treatment-related adverse events or Fabry-associated clinical events (FACEs) between\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      and\n                      <jats:italic>T<\/jats:italic>\n                      <jats:sub>+1<\/jats:sub>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      Females showed a stable disease course independent of the concomitant treatment with SGLT2i. Males showed an eGFR decrease of 3.7\u00a0ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      per year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0018) before and an ameliorated decrease of 2.7\u00a0ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      per year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0182) after SGLT2i initiation. Importantly, a slight but significant improvement of LVEF by 0.6% per year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0319) was observed, which was more prominent in males with a reduced LVEF (&lt;\u200950%) at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with SGLT2i of FD patients was safe and patients presented with stable disease courses. Especially males with reduced LVEF might benefit from SGLT2i treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02886-7","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:55:49Z","timestamp":1773042949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of SGLT2 inhibitors in patients with Fabry disease"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-2886","authenticated-orcid":false,"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Kurschat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Gatterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Sokalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"2886_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","volume":"25","author":"S Feriozzi","year":"2021","unstructured":"Feriozzi S, Rozenfeld P (2021) Pathology and pathogenic pathways in Fabry nephropathy. Clin Exp Nephrol 25:925\u2013934","journal-title":"Clin Exp Nephrol"},{"key":"2886_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/eurheartj\/ehae148","volume":"45","author":"M Pieroni","year":"2024","unstructured":"Pieroni M, Namdar M, Olivotto I, Desnick RJ (2024) Anderson-Fabry disease management: role of the cardiologist. Eur Heart J 45:1395\u20131409","journal-title":"Eur Heart J"},{"key":"2886_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B et al (2015) Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet 52:860\u2013866","journal-title":"J Med Genet"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44:3627\u20133639","journal-title":"Eur Heart J"},{"key":"2886_CR6","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO (2024) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (105):S117\u2013S314","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2886_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/imj.16603","volume":"55","author":"A Tsatsaronis","year":"2025","unstructured":"Tsatsaronis A, Tiong M, Nicholls K, Ruderman I (2025) Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series. Intern Med J 55:617\u2013621","journal-title":"Intern Med J"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334","journal-title":"N Engl J Med"},{"key":"2886_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"2886_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","volume":"99","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Mehta AB, Hilz MJ et al (2010) A validated disease severity scoring system for Fabry disease. Mol Genet Metab 99:283\u2013290","journal-title":"Mol Genet Metab"},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.pain.2014.08.024","volume":"155","author":"N \u00dc\u00e7eyler","year":"2014","unstructured":"\u00dc\u00e7eyler N, Magg B, Thomas P et al (2014) A comprehensive Fabry-related pain questionnaire for adult patients. Pain 155:2301\u20132305","journal-title":"Pain"},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299\u2013307","journal-title":"Clin Genet"},{"key":"2886_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jmg-2022-108669","volume":"60","author":"DA Hughes","year":"2023","unstructured":"Hughes DA, Bichet DG, Giugliani R et al (2023) Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet 60:722\u2013773","journal-title":"J Med Genet"},{"key":"2886_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K et al (2021) Effect of empaglifozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143:516\u2013525","journal-title":"Circulation"},{"key":"2886_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77:243\u2013255","journal-title":"J Am Coll Cardiol"},{"key":"2886_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation 140:1693\u20131702","journal-title":"Circulation"},{"key":"2886_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M et al (2021) Associations of empaglifozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF randomized clinical trial. JAMA Cardiol 6:836\u2013840","journal-title":"JAMA Cardiol"},{"key":"2886_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A et al (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89:44\u201354","journal-title":"Clin Genet"},{"key":"2886_CR19","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM et al (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45:3912\u20134018","journal-title":"Eur Heart J"},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10741-022-10256-4","volume":"28","author":"G Novo","year":"2023","unstructured":"Novo G, Guarino T, Di Lisi D, Biagioli P, Carluccio E (2023) Effects of SGLT2 inhibitors on cardiac structure and function. Heart Fail Rev 28:697\u2013707","journal-title":"Heart Fail Rev"},{"key":"2886_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"2886_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"2886_CR23","doi-asserted-by":"crossref","unstructured":"van der Aart- Beek AB, de Boer RA, Heerspink HJL (2022) Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 18:294\u2013306","DOI":"10.1038\/s41581-022-00535-6"},{"key":"2886_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"17","author":"RA DeFronzo","year":"2021","unstructured":"DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17:319\u2013334","journal-title":"Nat Rev Nephrol"},{"key":"2886_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","volume":"33","author":"T Sen","year":"2021","unstructured":"Sen T, Heerspink HJL (2021) A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab 33:732\u2013739","journal-title":"Cell Metab"},{"key":"2886_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","volume":"72","author":"SS Waikar","year":"2018","unstructured":"Waikar SS, Rebholz CM, Zheng Z et al (2018) Biological variability of estimated GFR and albuminuria in CKD. Am J Kidney Dis 72:538\u2013546","journal-title":"Am J Kidney Dis"},{"key":"2886_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","volume":"81","author":"MS Khan","year":"2023","unstructured":"Khan MS, Shahid I, Anker SD et al (2023) Albuminuria and heart failure: JACC state-of-the-art review. J Am Coll Cardiol 81:270\u2013282","journal-title":"J Am Coll Cardiol"},{"key":"2886_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney Foundation","year":"2012","unstructured":"National Kidney Foundation (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60:850\u2013886","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02886-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:55:51Z","timestamp":1773042951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02886-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":28,"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02886-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All investigations were performed after approval by the respective ethics committees of the participating centers (project number: 2011\u2013347-f-s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from patients where appropriate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Malte Lenders received speaker honoraria, travel funding, and research grants from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. Eva Brand received research grants and speaker honoraria from Sanofi, Takeda, Chiesi, Eleva, and Amicus Therapeutics. Albina Nowak received speaker honoraria and research grants from Amicus, Takeda, and Sanofi. Christine Kurschat received speaker honoraria and travel support from Amicus Therapeutics, Chiesi, Eleva, Sanofi, and Takeda. Markus Cybulla received speaker honoraria\/travel grants from Takeda, Amicus Therapeutics, Idorsia, and Alexion. Sima Canaan-K\u00fchl received speaker honoraria and travel funding from Sanofi, Takeda, Chiesi, Eleva, and Amicus Therapeutics.\u00a0Fabian Braun received speaker honoraria, travel funding, and research grants from Amicus Therapeutics, Sanofi, Chiesi, and Takeda. Constantin Gatterer received speaker honoraria and\/or research grants and\/or travel grants from Amicus Therapeutics, Chiesi, Sanofi-Genzyme, and Takeda.\u00a0Gere Sunder-Plassmann received honoraria, travel grants, study fees or research grants from Amicus Therapeutics, Sanofi-Genzyme, Chiesi, Freeline, and Idorsia.\u00a0Victoria Sokalski received speaker honoraria, travel funding, and research grants from Amicus Therapeutics, Sanofi, Takeda, and Chiesi.\u00a0Peter Nordbeck received speaker\/advisory board honoraria and research grants from Amicus Therapeutics, Boehringer Ingelheim, Chiesi, Idorsia, Pfizer, Sangamo, Sanofi-Genzyme, and Takeda.\u00a0Christoph Wanner received speaker\/advisory board honoraria from Amicus Therapeutics, Boehringer Ingelheim, Chiesi, Idorsia, and Sanofi-Genzyme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}